Pomalong 4mg capsules | Pomalidomide | MHP
POMALONG 4MG
 |
MULTIPLE MYELOMA |
DESCRIPTION
Pomalidomide is sold under the brand name Pomalong 4mg and it belongs to anti-neoplastic drugs
Pomalong 4mg is doable as orally bioavailable thalidomide derivative associated with numerous therapeutic activities such as: immune modulatory, anti-angiogenesis, anti-neoplastic.
Pomalong 4mg combination with dexamethasone will cause liver injury
CLINICAL USE
The primary indication of Pomalong 4mg capsules is used in the treatment of Multiple Myeloma condition.
In this condition, Pomalong 4mg capsules is used by combining with dexamethasone.
Pomalong 4mg capsules are applicable in;
Previously the Patients treated with two treatment such as proteasome inhibitor & Lenalidomide.
Patients who are suffered with disease progression condition
Pomalong 4mg treatment should be followed within 60 days in patients who are concluded the last treatment.
MECHANISM OF ACTION
Pomalong has three primary pharmacological activities against cancer cells.
Pomalidomide includes in the way cancer proliferation and provoke the apoptosis of cancer cells.
Pomalidomide enhance the T cell & natural killer cells interceding immunity & inhibits the formation of pro inflammatory cytokines from monocytes.
Pomalidomide forbid the new cell formation. The binding of Pomalidomide to active site of targeted cell causes inhibition of ubiquitin ligase action.
Ingredients : Pomalidomide
Strength : 4mg
Manufactured : Cipla Ltd
Package : 21 capsules
PHARMACOKINETICS
The time to high serum concentration of Pomalidomide is reaches between 2 to 3 hours.
It should be administered with or without food. Hence No effect of food should be produced;
Volume of distribution of Pomalidomide is between 62 & 138L in steady state.
The Pomalidomide distribution by 67% of serum level at after 4 hours of drug intake.
human plasma protein by bounding range of 12% & 44%.
Hepatically mediated through CYP1A2, CYP3A4 is Pomalidomide is metabolized.
Pomalidomide clearance value is 7 to 10L/hr.
Doses are excreted via urine 73% & feces 15% respectively.
Doses are excreted as an unchanged form via urine 2% & feces 8%.
Pomalidomide half-life period is 9.5 hours.
DOSAGE MANAGEMENT
During multiple myeloma malignancies;
The dosage recommendation of Pomalong 4mg is 4mg should be administered as a single dose for 1 to 21 days of successive 28-day cycles.
Pomalong is combined with dexamethasone with low dose.
Administrate Dexamethasone on day 1, 8, 15 & 22 of each 28-day cycle.
The prescribed dose of dexamethasone is 40mg should be administered the patient having weight about ≤ 75kg.
The prescribed dose of dexamethasone is 20mg given for patient’s weight Greater than 75kg
Dosage alteration during hematological toxicities;
Neutropenia;
ANC <500/mcL: Pomalong treatment should be postponed and check the CBC weekly.
ANC ≥ 500/mcL: Pomalong therapy should be continued by 3mg/day
For each successive drop <500/mcL: Pomalong 4mg should be postponed.
ANC ≥ 500/mcL: Continue the Pomalong therapy with 1mg/day.
Thrombocytopenia;
Platelets count <25000/mcL: Pomalong therapy should be postponed and check CBC
Platelets count ≥50000/mcL: 3mg of Pomalong should be taken daily
With strong CYP1A2;
Pomalong combined with CYP1A2 substrates causes increasing the plasma concentration of Pomalidomide and leads to elevate the risk of Pomalidomide.
In renal damaged patients;
In severe renal impaired patients, the suggested dose of Pomalong is 3mg per day.
In hepatic impaired patients;
The advised dose is 3mg/day & in severe condition, the suggested dose is 2mg/day given for mild to moderate patients.
Embryo fetal damage;
Pomalong 4mg should be contraindicated to pregnancy causes Teratogenicity, organogenesis and causes fetal damage.
Avoid becoming pregnant during Pomalong 4mg therapy by using effective contraceptives.
Venous & arterial thromboembolism;
Deep vein thrombosis is risk condition occurs during the Pomalong 4mg treatment.
Thromboprophylaxis is initiated for this condition.
In case of pembrolizumab given to thalidomide & dexamethasone causes Elevation of mortality
Pembrolizumab combined with dexamethasone causes mortality in high range in multiple myeloma condition.
The combination of PD-1 or PD-L1 blocking agent with thalidomide analogue with dexamethasone has not evaluated.
Hematological toxicity;
Neutropenia, thrombocytopenia is most common adverse effects occur during the Pomalong 4mgtreatment.
These may negate by checking the blood counts frequently and postponement of dosage or adjustment of dose is necessary.
Liver toxicity;
During Pomalong 4mg treatment, there is a chance of elevation of hepatic enzymes occurs.
This may result as increased liver toxicity.
Neuropathy;
Pomalong 4mg combined with low dose of dexamethasone causes peripheral neuropathy in some patients.
Prevent the treatment until toxicity grade chances to 1 or 0
Exposure of second primary malignancies;
Pomalong 4mg receiving patients has high chances of getting second primary malignancies.
Tumor lysis syndrome;
This condition is majorly occurred in Pomalong 4mg receiving patients.
Monitor the manifestation due to this condition
Appropriate management should be provided
FOR FURTHER INFORMATION
MOBILE NO : 91-9940472902EMAIL : millionhealthpharmaceuticals@gmail.com
WEBSITE URL : https://millionpharma.com/pomalong-4mg.php
Comments
Post a Comment